167 related articles for article (PubMed ID: 10192890)
1. Intensive therapy in multiple myeloma.
Harousseau JL
Pathol Biol (Paris); 1999 Feb; 47(2):203-9. PubMed ID: 10192890
[TBL] [Abstract][Full Text] [Related]
2. [Intensive treatment of multiple myeloma].
Harousseau JL
Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
[TBL] [Abstract][Full Text] [Related]
3. The role of autologous hematopoietic stem cell transplantation in multiple myeloma.
Harousseau JL; Attal M
Semin Hematol; 1997 Jan; 34(1 Suppl 1):61-6. PubMed ID: 9122747
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Attal M; Harousseau JL; Stoppa AM; Sotto JJ; Fuzibet JG; Rossi JF; Casassus P; Maisonneuve H; Facon T; Ifrah N; Payen C; Bataille R
N Engl J Med; 1996 Jul; 335(2):91-7. PubMed ID: 8649495
[TBL] [Abstract][Full Text] [Related]
5. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
[TBL] [Abstract][Full Text] [Related]
7. [Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].
Attal M; Harousseau JL
Bull Cancer; 2001 Sep; 88(9):888-92. PubMed ID: 11604362
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
[TBL] [Abstract][Full Text] [Related]
9. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
10. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
Björkstrand B; Gahrton G
Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
[TBL] [Abstract][Full Text] [Related]
11. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
Gibson J; Ho PJ; Joshua D
Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution.
Bladé J; Esteve J; Rives S; Martínez C; Rovira M; Urbano-Ispizua A; Marín P; Carreras E; Montserrat E
Bone Marrow Transplant; 2000 Oct; 26(8):845-9. PubMed ID: 11081383
[TBL] [Abstract][Full Text] [Related]
13. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma.
Abraham R; Chen C; Tsang R; Simpson D; Murray C; Davidson M; Meharchand J; Sutton DM; Crump RM; Keating A; Stewart AK
Bone Marrow Transplant; 1999 Dec; 24(12):1291-7. PubMed ID: 10627637
[TBL] [Abstract][Full Text] [Related]
14. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports.
Cavo M; Benni M; Cirio TM; Gozzetti A; Tura S
Stem Cells; 1995 Aug; 13 Suppl 2():126-31. PubMed ID: 8520501
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma.
Reece DE; Brockington DA; Phillips GL; Barnett MJ; Klingemann HG; Nantel SH; Sutherland HJ; Shepherd JD
Bone Marrow Transplant; 2000 Sep; 26(6):621-6. PubMed ID: 11041567
[TBL] [Abstract][Full Text] [Related]
17. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
18. Intensive treatment strategies in multiple myeloma.
Kovacsovics TJ; Delaly A
Semin Hematol; 1997 Jan; 34(1 Suppl 1):49-60. PubMed ID: 9122746
[TBL] [Abstract][Full Text] [Related]
19. Role of stem cell transplantation.
Harousseau JL
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]